Latest Ratios: P/E Ratio 20.4x · EV/EBITDA 15.5x · ROE 35.5%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14.3B | $12.3B | $10.1B | $7.7B | $5.2B | $5.9B | $6.4B | $5.6B | $6.2B | $9.5B | $3.7B |
| Enterprise Value | $13.9B | $12.0B | $10.0B | $7.6B | $4.9B | $5.3B | $6.1B | $5.3B | $5.9B | $9.3B | $3.8B |
| P/E Ratio → | 20.41 | 15.68 | 19.30 | 36.91 | 28.64 | 25.39 | 57.34 | 17.27 | 8.90 | 62.04 | — |
| P/S Ratio | 6.15 | 5.29 | 4.64 | 4.21 | 3.23 | 4.11 | 6.46 | 5.74 | 7.21 | 20.96 | 19.51 |
| P/B Ratio | 7.40 | 5.68 | 4.48 | 3.41 | 2.09 | 2.67 | 3.40 | 3.29 | 4.78 | 33.28 | 41.82 |
| P/FCF | 16.89 | 14.55 | 15.87 | 45.27 | 23.22 | 17.51 | 35.73 | 10.80 | 16.09 | 65.65 | 18.26 |
| P/OCF | 16.13 | 13.89 | 14.37 | 23.14 | 14.36 | 14.70 | 30.54 | 10.53 | 14.80 | 57.27 | 18.11 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.16 | 4.63 | 4.17 | 3.04 | 3.69 | 6.19 | 5.51 | 6.85 | 20.59 | 19.71 |
| EV / EBITDA | 15.48 | 13.29 | 15.84 | 38.85 | 22.01 | 17.64 | 51.28 | 14.02 | 13.19 | 55.75 | — |
| EV / EBIT | 15.99 | 13.41 | 14.54 | 29.66 | 20.89 | 18.01 | 55.53 | 13.40 | 13.34 | 55.75 | — |
| EV / FCF | — | 14.18 | 15.83 | 44.84 | 21.84 | 15.74 | 34.22 | 10.38 | 15.30 | 64.49 | 18.44 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.4% | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% | 96.3% | 96.6% | 96.9% | 96.7% | 96.6% |
| Operating Margin | 37.6% | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | -14.7% |
| Net Profit Margin | 33.7% | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | -36.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 35.5% | 35.5% | 23.1% | 8.7% | 7.8% | 11.3% | 6.3% | 21.6% | 87.8% | 82.4% | -78.6% |
| ROA | 27.0% | 27.0% | 17.7% | 6.9% | 6.4% | 9.7% | 5.6% | 19.4% | 66.4% | 24.6% | -15.1% |
| ROIC | 32.1% | 32.1% | 20.6% | 5.9% | 8.0% | 13.3% | 5.4% | 22.5% | 59.6% | 102.4% | -16.1% |
| ROCE | 35.0% | 35.0% | 23.7% | 6.5% | 8.0% | 13.6% | 6.0% | 24.2% | 47.3% | 38.3% | -9.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.09 | 0.08 | 0.08 | 0.02 | 0.03 | 0.03 | 0.01 | 0.05 | 2.12 |
| Debt / EBITDA | 0.19 | 0.19 | 0.30 | 0.97 | 0.86 | 0.17 | 0.41 | 0.13 | 0.03 | 0.09 | — |
| Net Debt / Equity | — | -0.14 | -0.01 | -0.03 | -0.12 | -0.27 | -0.14 | -0.13 | -0.23 | -0.59 | 0.42 |
| Net Debt / EBITDA | -0.34 | -0.34 | -0.04 | -0.37 | -1.40 | -1.98 | -2.27 | -0.57 | -0.68 | -1.01 | — |
| Debt / FCF | — | -0.37 | -0.04 | -0.43 | -1.39 | -1.77 | -1.51 | -0.42 | -0.78 | -1.17 | 0.18 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | 19.25 | -1.12 |
Net cash position: cash ($482M) exceeds total debt ($173M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.56 | 3.56 | 3.63 | 3.34 | 4.99 | 5.43 | 7.06 | 7.08 | 8.50 | 4.21 | 1.74 |
| Quick Ratio | 3.50 | 3.50 | 3.58 | 3.30 | 4.89 | 5.35 | 6.96 | 6.99 | 8.41 | 4.15 | 1.73 |
| Cash Ratio | 2.61 | 2.61 | 2.75 | 2.52 | 4.03 | 4.35 | 5.90 | 5.97 | 6.57 | 3.37 | 1.55 |
| Asset Turnover | — | 0.82 | 0.74 | 0.62 | 0.52 | 0.55 | 0.46 | 0.51 | 0.60 | 0.69 | 0.32 |
| Inventory Turnover | 3.86 | 3.86 | 3.40 | 4.19 | 1.74 | 1.92 | 1.73 | 2.57 | 2.68 | 2.26 | 1.96 |
| Days Sales Outstanding | — | 45.14 | 44.67 | 47.35 | 48.66 | 72.63 | 59.46 | 44.91 | 69.58 | 65.50 | 77.11 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.9% | 6.4% | 5.2% | 2.7% | 3.5% | 3.9% | 1.7% | 5.8% | 11.2% | 1.6% | — |
| FCF Yield | 5.9% | 6.9% | 6.3% | 2.2% | 4.3% | 5.7% | 2.8% | 9.3% | 6.2% | 1.5% | 5.5% |
| Buyback Yield | 6.6% | 7.7% | 6.5% | 7.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% |
| Total Shareholder Yield | 6.6% | 7.7% | 6.5% | 7.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% |
| Shares Outstanding | — | $282M | $296M | $321M | $325M | $322M | $318M | $315M | $313M | $312M | $251M |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EXEL stock.
Exelixis, Inc.'s current P/E ratio is 20.4x. The historical average is 28.0x. This places it at the 50th percentile of its historical range.
Exelixis, Inc.'s current EV/EBITDA is 15.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.9x.
Exelixis, Inc.'s return on equity (ROE) is 35.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -31.9%.
Based on historical data, Exelixis, Inc. is trading at a P/E of 20.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Exelixis, Inc. has 96.4% gross margin and 37.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Exelixis, Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Revenue concentration in cabozantinib
Metrics are mathematically derived from official filings.
Margin Expansion Driven by Operating Leverage
Operating margin expanded to 39.5% in 2026Q2 from 33.6% in 2025Q1, per financial statements, reflecting strong operating leverage and cost discipline, with gross margin stable near 96.7%.
The sequential improvement in operating margin from 33.6% in 2025Q1 to 39.5% in 2026Q2, as reported in financial statements, suggests that revenue growth is flowing through to the bottom line faster than costs, a classic sign of operating leverage in an asset-light model. Net margin also improved to 33.7% in 2026Q2 from 28.7% in 2025Q1, though the 2025Q4 spike to 40.8% likely included a one-time tax benefit, warranting scrutiny. The sustainability of these margins depends on continued revenue growth and disciplined R&D spending, which declined as a percentage of revenue from 43.9% in 2024Q1 to 33.7% in 2026Q2.
ROIC Recovery Signals Compounding Efficiency
ROIC climbed to 10.3% in 2026Q2 from 4.7% in 2024Q3, according to recent SEC filings, indicating improved capital efficiency, though still below peer INCY's 51.1%.
The doubling of ROIC from 4.7% in 2024Q3 to 10.3% in 2026Q2, based on reported figures, suggests that the company is generating higher returns on its invested capital, driven by margin expansion rather than asset turnover, which remained low at 0.25. ROE also improved to 11.2% in 2026Q2 from 5.4% in 2024Q3, but this is partly flattered by share buybacks reducing equity. The gap to INCY's ROIC of 51.1% highlights that Exelixis still has room to improve capital efficiency, but the trend is positive.
Working Capital Efficiency Shows Mixed Signals
Cash conversion cycle turned positive to 30 days in 2026Q2 from -84 days in 2024Q4, per financial statements, as DPO compressed sharply, indicating a shift in supplier payment terms.
The CCC swung from -84 days in 2024Q4 to +30 days in 2026Q2, driven by a dramatic reduction in days payable outstanding from 232 to 139, as reported in financial statements. This suggests that Exelixis is paying suppliers faster, possibly to secure supply or due to changing terms, which reduces the cash buffer provided by payables. DSO remained stable around 46 days, while DIO increased to 122 days from 103, indicating higher inventory levels, which may warrant monitoring for obsolescence risk in a biotech context.
Minimal Leverage Masks Buyback-Driven Cash Burn
Debt-to-equity remains low at 0.09 with D/EBITDA at 0.63, per balance sheet data, but aggressive buybacks consumed cash, reducing the liquidity buffer from $482.5M to $281.4M in 2026Q2.
Exelixis' conservative capital structure, with D/E of 0.09 and D/EBITDA of 0.63 in 2026Q2, indicates minimal refinancing risk and ample interest coverage, though interest coverage data is unavailable. However, the balance sheet shows cash declining from $482.5M in 2025Q4 to $281.4M in 2026Q2, as per recent filings, due to $753.3M in buybacks exceeding operating cash flow of $559.6M. This suggests that while leverage is low, the company is using its cash reserves to fund buybacks, which could strain liquidity if cash generation falters.
Liquidity Ratios Strong but Buffer Thinning
Current ratio remains healthy at 3.46 in 2026Q2, per balance sheet data, but cash reserves fell sharply from $482.5M to $281.4M, suggesting a shrinking cushion against operational shocks.
The current ratio of 3.46 and quick ratio of 3.38 in 2026Q2, as reported in financial statements, indicate that Exelixis can cover short-term obligations comfortably, with inventory playing a minor role. However, the absolute cash balance dropped by $201.1M from 2025Q4 to 2026Q2, reflecting aggressive buybacks, which reduces the buffer available for unexpected R&D needs or market downturns. While the ratios remain strong, the trend in cash reserves warrants monitoring, especially if revenue growth slows.
P/E Misleading for Asset-Light Biotech
P/E of 19.05 understates value for an asset-light biotech with 89% FCF margin, per financial statements, as earnings are inflated by tax benefits and buybacks; EV/EBITDA of 14.43 is more relevant.
The P/E ratio is commonly misapplied to Exelixis because net income is distorted by one-time tax items and share buybacks, which reduce equity and inflate EPS. In 2025Q4, net margin spiked to 40.8% likely due to a tax benefit, making P/E unreliable. Instead, EV/EBITDA of 14.43 and P/FCF of 15.77 provide a cleaner picture of valuation, as they focus on operating performance and cash generation, which are robust with FCF margin at 89.0% in 2026Q2. Investors should use EV/EBITDA or P/FCF to compare Exelixis to peers like INCY and ALKS, as these metrics better capture the economics of an asset-light, high-margin biotech.